Our lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases. Based on results from cellular and animal studies, we believe Sarconeos (BIO101) stimulates biological resilience through activation of the MAS receptor and may have the potential to improve muscle function and preserve strength, mobility and respiratory capacity in various age-related and muscular wasting conditions.
POTENTIAL MECHANISM OF ACTION
Our preclinical studies have demonstrated that Sarconeos (BIO101) activates the MAS receptor in muscle cells, a key component of the renin-angiotensin system (RAS). The RAS is a fundamental endocrine system that is known to control fluid balance, blood pressure and cardio-vascular function. The RAS is also involved in the regulation of smooth, cardiac and skeletal muscle metabolism and plays a key role in muscle function and mobility in disease states.
The potential mechanism-of-action of Sarconeos (BIO101) is illustrated below:
Sarconeos (BIO101), through the activation of the MAS receptor, triggers three downstream signaling pathways that that are impaired in many muscle wasting conditions:
- P13K/AKT/mTOR pathway – known to be responsible for increasing protein synthesis. We believe activating this pathway is a key factor for preserving muscle mass and increasing muscle strength under muscle wasting conditions.
- MAPK/P38/JNK pathway – known to be involved in stem cell proliferation and differentiation. We believe activating this pathway is a key factor for improving muscle regeneration.
- AMPK/ACC pathway – known to be involved in stimulating energy production. We believe activating this pathway may be a key factor for increasing muscle strength and improved endurance.